¼¼°èÀÇ »çÀ̹ö³ªÀÌÇÁ ½ÃÀå
CyberKnife
»óǰÄÚµå : 1786353
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 282 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,150,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,452,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ »çÀ̹ö³ªÀÌÇÁ ½ÃÀåÀº 2030³â±îÁö 17¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 6¾ï 1,840¸¸ ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼¼°èÀÇ »çÀ̹ö³ªÀÌÇÁ ½ÃÀåÀº 2024-2030³âÀÇ ºÐ¼® ±â°£¿¡ CAGR 18.5%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 17¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ¸®Æ÷Æ®¿¡¼­ ºÐ¼®ÇÑ ºÎ¹®ÀÇ ÇϳªÀÎ ¾Ï ¾ÖÇø®ÄÉÀ̼ÇÀº CAGR 20.0%¸¦ ±â·ÏÇϸç, ºÐ¼® ±â°£ Á¾·á±îÁö 11¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. Á¾¾ç ¾ÖÇø®ÄÉÀÌ¼Ç ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ Áß CAGR 17.3%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 1¾ï 6,850¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 24.5%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ »çÀ̹ö³ªÀÌÇÁ ½ÃÀåÀº 2024³â¿¡ 1¾ï 6,850¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦´ë±¹ÀÎ Áß±¹Àº ºÐ¼® ±â°£ÀÎ 2024-2030³âÀÇ CAGRÀ» 24.5%·Î, 2030³â±îÁö 3¾ï 8,750¸¸ ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, °¢°¢ ºÐ¼® ±â°£ Áß 13.6%¿Í 16.8%ÀÇ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR ¾à 14.8%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ »çÀ̹ö³ªÀÌÇÁ ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ Á¤¸®

»çÀ̹ö³ªÀÌÇÁ°¡ Á¤¹Ð ¹æ»ç¼± Ä¡·á¿¡¼­ ÀÎÁ¤¹Þ´Â ÀÌÀ¯´Â?

ÃÖ÷´Ü ·Îº¿ ¹æ»ç¼± ¼ö¼ú ½Ã½ºÅÛÀÎ »çÀ̹ö³ªÀÌÇÁ´Â ºñħ½ÀÀûÀ̰í Á¤¹ÐÇÑ ¹æ»ç¼± Ä¡·á¸¦ Á¦°øÇÔÀ¸·Î½á ¾Ï Ä¡·á¿¡ Çõ¸íÀ» ÀÏÀ¸Ä×½À´Ï´Ù. ±âÁ¸ ¹æ»ç¼± ±â¼ú°ú ´Þ¸® »çÀ̹ö³ªÀÌÇÁ´Â ½Ç½Ã°£ ¿µ»ó ¾È³»¿Í ·Îº¿ ±â¼úÀ» Ȱ¿ëÇØ ¹Ð¸®¹ÌÅÍ ÀÌÇÏÀÇ Á¤¹Ðµµ·Î Á¾¾çÀ» Á¶ÁØÇϰí ÁÖº¯ °Ç°­ÇÑ Á¶Á÷ÀÇ ¼Õ»óÀ» ÃÖ¼ÒÈ­ÇÕ´Ï´Ù. À̸¦ ÅëÇØ ³úÁ¾¾ç, Àü¸³¼±¾Ï, Æó¾Ï, ôÃß¾Ï, ÃéÀå¾Ï µî º¹ÀâÇÑ ¾Ï Ä¡·á¿¡ ÇʼöÀûÀÎ ÅøÀÌ µÇ°í ÀÖ½À´Ï´Ù.

¼¼°è¿¡¼­ ¾Ï ¹ßº´·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ÷´Ü ¹æ»ç¼± Ä¡·á ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖÀ¸¸ç, »çÀ̹ö³ªÀÌÇÁ´Â ÅëÁõÀÌ ¾ø´Â ¿Ü·¡ Ä¡·á¸¦ ¿øÇϴ ȯÀڵ鿡°Ô ¼±È£µÇ´Â Ä¡·á¹ýÀ¸·Î ºÎ»óÇϰí ÀÖ½À´Ï´Ù. »çÀ̹ö³ªÀÌÇÁ´Â ƯÈ÷ Æó¾Ï, Àü¸³¼±¾Ï µî ȯÀÚÀÇ ¿òÁ÷ÀÓ¿¡ ÀûÀÀÇÒ ¼ö ÀÖÀ¸¸ç, Ä¡·á È¿°ú¿Í ȯÀÚÀÇ Æí¾ÈÇÔÀ» Çâ»ó½Ãŵ´Ï´Ù. ¶ÇÇÑ Á¤À§Àû ¹æ»ç¼± Ä¡·á(SBRT)¿Í Á¤À§Àû ¹æ»ç¼± ¼ö¼ú(SRS)ÀÇ Ã¤ÅÃÀÌ Áõ°¡Çϰí ÀÖÀ¸¸ç, Àü ¼¼°è ÁÖ¿ä Á¾¾ç ¼¾ÅÍ¿¡¼­ »çÀ̹ö³ªÀÌÇÁ ½Ã½ºÅÛÀÇ ÅëÇÕÀÌ ÃßÁøµÇ°í ÀÖ½À´Ï´Ù.

»çÀ̹ö³ªÀÌÇÁ ½Ã½ºÅÛÀÇ Ãֽбâ¼ú ¹ßÀüÀº?

·Îº¿ ¹æ»ç¼± ¼ö¼úÀÇ ²÷ÀÓ¾ø´Â ±â¼ú Çõ½ÅÀº »çÀ̹ö³ªÀÌÇÁÀÇ ´É·ÂÀ» Å©°Ô Çâ»ó½ÃÄÑ Ä¡·áÀÇ Á¤È®¼º, È¿À²¼º, ¾ÈÀü¼ºÀ» ³ô¿´½À´Ï´Ù. °¡Àå ÁÖ¸ñÇÒ ¸¸ÇÑ ¹ßÀü Áß Çϳª´Â AI¸¦ ÅëÇÑ Á¾¾ç ÃßÀû ±â´ÉÀ» ÅëÇÕÇÏ¿© ȯÀÚÀÇ ¿òÁ÷ÀÓ¿¡ µû¶ó ½Ç½Ã°£À¸·Î ¹æ»ç¼± ºöÀ» Á¶Á¤ÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù´Â Á¡ÀÔ´Ï´Ù. À̴ ȣÈí ¿îµ¿ÀÌ Ç¥Àû Á¤È®µµ¿¡ ¿µÇâÀ» ¹ÌÄ¥ ¼ö ÀÖ´Â Æó¿Í °°Àº À̵¿¼º Àå±âÀÇ Á¾¾ç Ä¡·á¿¡ ƯÈ÷ À¯¿ëÇÕ´Ï´Ù.

¶Ç ´Ù¸¥ µ¹ÆÄ±¸´Â ´õ ³ôÀº ¼±·®À» ´õ ªÀº Ä¡·á½Ã°£¿¡ Á¶»çÇÏ¿© Ä¡·á Ƚ¼ö¸¦ ÁÙÀÌ´Â Â÷¼¼´ë ¼±Çü °¡¼Ó±â(¼±Çü¸¯)ÀÇ °³¹ßÀÔ´Ï´Ù. ¶ÇÇÑ MRI À¯µµÇÏ ¹æ»ç¼± ¼ö¼ú, ÀûÀÀÇü ¹æ»ç¼± Ä¡·á µî ÷´Ü ¿µ»ó Áø´ÜÀÌ »çÀ̹ö³ªÀÌÇÁ ½Ã½ºÅÛ°ú ÅëÇյǾî Ä¡·á °èȹÀÇ Á¤±³È­¿Í ÀÓ»óÀû ¼º°ú Çâ»óÀ» µµ¸ðÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ Å¬¶ó¿ìµå ±â¹Ý Ä¡·á °èȹ ¹× ¿ø°Ý ¸ð´ÏÅ͸µ ±â´Éµµ È®´ëµÇ¾î Á¾¾ç Àü¹®Àǰ¡ ¿ø°ÝÀ¸·Î Çù·ÂÇÏ¿© Ä¡·á ÇÁ·ÎÅäÄÝÀ» Á¶Á¤ÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù.

½ÃÀå µ¿Çâ°ú ÇコÄɾî Á¤Ã¥Àº »çÀ̹ö³ªÀÌÇÁ µµÀÔ¿¡ ¾î¶² ¿µÇâÀ» ¹ÌÄ¡°í Àִ°¡?

»çÀ̹ö³ªÀÌÇÁÀÇ Ã¤ÅÃÀº ºñħ½ÀÀû ¾Ï Ä¡·á·ÎÀÇ Àüȯ, ȯÀÚ Áß½É Ä¡·á¿¡ ´ëÇÑ °ü½É Áõ°¡, ¹æ»ç¼± ¼ö¼úÀÇ º¸Çè Àû¿ë ¹üÀ§ È®´ë µî ÁøÈ­ÇÏ´Â ÇコÄÉ¾î µ¿Çâ¿¡ ÀÇÇØ Çü¼ºµÇ°í ÀÖ½À´Ï´Ù. ½ÅÈï ½ÃÀåÀÇ ÇコÄɾî ÀÎÇÁ¶ó È®´ëµµ »çÀ̹ö³ªÀÌÇÁÀÇ º¸±Þ¿¡ ±â¿©Çϰí ÀÖÀ¸¸ç, º´¿øµéÀº Áõ°¡ÇÏ´Â ¾Ï Ä¡·á ¼ö¿ä¿¡ ´ëÀÀÇϱâ À§ÇØ ÃÖ÷´Ü Á¾¾çÇÐ ¼Ö·ç¼Ç¿¡ ÅõÀÚÇϰí ÀÖ½À´Ï´Ù.

FDA, À¯·´ÀǾàǰû(EMA) µî ±ÔÁ¦±â°üÀº ¹æ»ç¼± Ä¡·á ½Ã½ºÅÛÀÇ ¾ÈÀü¼º°ú À¯È¿¼ºÀ» º¸ÀåÇϱâ À§ÇØ Áö¼ÓÀûÀ¸·Î °¡À̵å¶óÀÎÀ» ¾÷µ¥ÀÌÆ®Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±ÔÁ¦·Î ÀÎÇØ »çÀ̹ö³ªÀÌÇÁ Á¦Á¶¾÷üµéÀº ǰÁú°ü¸®¸¦ °­È­Çϰí, AI¸¦ Ȱ¿ëÇÑ ¾ÈÀü ¸ÞÄ¿´ÏÁòÀ» °³¹ßÇϸç, ±¹Á¦ ¹æ»ç¼± Ä¡·á ±âÁØ Áؼö¸¦ Çâ»ó½ÃÄÑ¾ß ÇÏ´Â »óȲ¿¡ Á÷¸éÇØ ÀÖ½À´Ï´Ù. ¶ÇÇÑ »çÀ̹ö³ªÀÌÇÁÀÇ È¿´ÉÀ» Áö¿øÇÏ´Â Àӻ󿬱¸°¡ Áõ°¡ÇÔ¿¡ µû¶ó ÁÖ¿ä ¹æ»ç¼± ¼ö¼ú ¼Ö·ç¼ÇÀ¸·Î¼­ÀÇ ÀÔÁö°¡ °­È­µÇ°í ÀÖ½À´Ï´Ù.

»çÀ̹ö³ªÀÌÇÁ ½ÃÀåÀÇ ¼ºÀå ¿øµ¿·ÂÀº?

»çÀ̹ö³ªÀÌÇÁ ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀº ·Îº¿ ¹æ»ç¼± ¼ö¼úÀÇ ¹ßÀü, ¾Ï ¹ßº´·ü Áõ°¡, ºñħ½ÀÀû Ä¡·á¹ý¿¡ ´ëÇÑ ¼±È£µµ Áõ°¡ µîÀÔ´Ï´Ù. ´õ ¸¹Àº ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õµéÀÌ Á¤¹Ð ¹æ»ç¼± Ä¡·áÀÇ ÀÌÁ¡À» ÀνÄÇÏ°Ô µÇ¸é¼­ ¼±Áø±¹°ú °³¹ßµµ»ó±¹À» ¸··ÐÇÏ°í »çÀ̹ö³ªÀÌÇÁ ½Ã½ºÅÛ¿¡ ´ëÇÑ ÅõÀÚ°¡ È®´ëµÇ°í ÀÖ½À´Ï´Ù.

½Å°æ¿Ü°ú, Á¤Çü¿Ü°ú, ¼Ò¾Æ¹æ»ç¼±Ä¡·á¿¡¼­´Â º¸´Ù Á¤¹ÐÇϰí ÃÖ¼Òħ½ÀÀûÀÎ Ä¡·á¸¦ À§ÇØ »çÀ̹ö³ªÀÌÇÁ°¡ »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ȯÀÚ ¹× Á¾¾ç Àü¹®ÀÇµé »çÀÌ¿¡¼­ »çÀ̹ö³ªÀÌÇÁÀÇ ÀÎÁöµµ°¡ ³ô¾ÆÁø °Íµµ ½ÃÀå ¼ºÀåÀ» ÃËÁøÇϰí ÀÖÀ¸¸ç, ƯÈ÷ Ä¡·á °á°ú°¡ »ýÁ¸À² Çâ»ó°ú ºÎÀÛ¿ë °¨¼Ò¸¦ Áö¼ÓÀûÀ¸·Î ÀÔÁõÇϰí ÀÖÀ¸¸ç, ½ÃÀå ¼ºÀå¿¡ ÈûÀ» ½Ç¾îÁÖ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ¿Í ¹æ»ç¼± Ä¡·á ±â¼ú ±â¾÷ °£ÀÇ ÆÄÆ®³Ê½ÊÀº Çõ½ÅÀ» ÃËÁøÇϰí Á¢±Ù¼ºÀ» Çâ»ó½ÃŰ¸ç »çÀ̹ö³ªÀÌÇÁ Ä¡·á ÇÁ·ÎÅäÄÝÀÇ Áö¼ÓÀûÀÎ ¹ßÀüÀ» º¸ÀåÇÕ´Ï´Ù.

ºÎ¹®

¿ëµµ(¾Ï¿ëµµ, Á¾¾ç ¿ëµµ, Ç÷°ü ±âÇü ¿ëµµ, ±âŸ ¿ëµµ); ÃÖÁ¾ ¿ëµµ(º´¿ø ÃÖÁ¾ ¿ëµµ, ¿Ü·¡ ȯÀÚ ½Ã¼³ ÃÖÁ¾ ¿ëµµ, Á¶»ç¡¤Á¦Á¶ ÃÖÁ¾ ¿ëµµ)

Á¶»ç ´ë»ó ±â¾÷ÀÇ ¿¹

AI ÅëÇÕ

Global Industry Analysts´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI Åø¿¡ ÀÇÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM³ª ¾÷°è °íÀ¯ SLM¸¦ Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹ü¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾ç ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÔ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå °³¿ä

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global CyberKnife Market to Reach US$1.7 Billion by 2030

The global market for CyberKnife estimated at US$618.4 Million in the year 2024, is expected to reach US$1.7 Billion by 2030, growing at a CAGR of 18.5% over the analysis period 2024-2030. Cancer Application, one of the segments analyzed in the report, is expected to record a 20.0% CAGR and reach US$1.1 Billion by the end of the analysis period. Growth in the Tumor Application segment is estimated at 17.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$168.5 Million While China is Forecast to Grow at 24.5% CAGR

The CyberKnife market in the U.S. is estimated at US$168.5 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$387.5 Million by the year 2030 trailing a CAGR of 24.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 13.6% and 16.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 14.8% CAGR.

Global CyberKnife Market - Key Trends & Growth Drivers Summarized

Why Is CyberKnife Gaining Recognition in Precision Radiation Therapy?

CyberKnife, a state-of-the-art robotic radiosurgery system, has revolutionized cancer treatment by offering non-invasive, high-precision radiation therapy. Unlike traditional radiation techniques, CyberKnife utilizes real-time image guidance and robotic technology to target tumors with sub-millimeter accuracy, minimizing damage to surrounding healthy tissues. This has made it an essential tool in treating complex cancers, including brain, prostate, lung, spine, and pancreatic tumors.

The rising global cancer burden has intensified the demand for advanced radiotherapy solutions, with CyberKnife emerging as a preferred alternative for patients seeking pain-free, outpatient-based treatment. Its ability to adapt to patient movement, particularly in lung and prostate cancer cases, enhances treatment efficacy and patient comfort. Additionally, the growing adoption of stereotactic body radiation therapy (SBRT) and stereotactic radiosurgery (SRS) has propelled the integration of CyberKnife systems in leading oncology centers worldwide.

What Are the Latest Technological Advancements in CyberKnife Systems?

Continuous innovation in robotic radiosurgery has significantly improved CyberKnife’s capabilities, enhancing treatment accuracy, efficiency, and safety. One of the most notable advancements is the integration of AI-driven tumor tracking, allowing real-time adjustments to radiation beams based on patient movement. This is particularly beneficial for treating tumors in mobile organs, such as the lungs, where respiratory motion can affect targeting precision.

Another breakthrough is the development of next-generation linear accelerators, which deliver higher radiation doses in shorter treatment times, reducing the number of sessions required. Additionally, advanced imaging modalities, including MRI-guided radiosurgery and adaptive radiotherapy, are being integrated with CyberKnife systems to refine treatment planning and improve clinical outcomes. Cloud-based treatment planning and remote monitoring capabilities are also expanding, allowing oncologists to collaborate and adjust treatment protocols remotely.

How Are Market Trends and Healthcare Policies Influencing CyberKnife Adoption?

The adoption of CyberKnife is being shaped by evolving healthcare trends, including the shift toward non-invasive cancer treatments, increased focus on patient-centered care, and growing reimbursement coverage for radiosurgery procedures. The expansion of healthcare infrastructure in emerging markets has also contributed to CyberKnife’s adoption, as hospitals invest in cutting-edge oncology solutions to meet rising cancer treatment demands.

Regulatory agencies, including the FDA and the European Medicines Agency (EMA), are continuously updating guidelines to ensure the safety and efficacy of radiation therapy systems. These regulations have driven CyberKnife manufacturers to enhance quality control, develop AI-driven safety mechanisms, and improve compliance with international radiation therapy standards. Additionally, the rising number of clinical studies supporting CyberKnife’s efficacy is strengthening its position as a leading radiosurgery solution.

What Is Driving the Growth of the CyberKnife Market?

The growth in the CyberKnife market is driven by advancements in robotic radiosurgery, increasing cancer incidence rates, and the growing preference for non-invasive treatment modalities. As more healthcare providers recognize the benefits of precision radiation therapy, investments in CyberKnife systems are expanding across developed and developing regions.

End-use expansion is another key factor, with neurosurgery, orthopedic oncology, and pediatric radiation therapy incorporating CyberKnife for more precise, minimally invasive treatments. The rising awareness of CyberKnife among patients and oncologists is also fueling market growth, particularly as treatment outcomes continue to demonstrate improved survival rates and reduced side effects. Additionally, partnerships between healthcare providers and radiotherapy technology firms are fostering innovation, enhancing accessibility, and ensuring continued advancements in CyberKnife treatment protocols.

SCOPE OF STUDY:

The report analyzes the CyberKnife market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Application (Cancer Application, Tumor Application, Vascular Malformation Application, Other Applications); End-Use (Hospitals End-Use, Outpatient Facilities End-Use, Research and Manufacturing End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â